key: cord-0723572-0n4jq1m3
authors: LEE, TERRY; CAU, A; CHENG, MP; LEVIN, A; LEE, TC; VINH, DC; LAMONTAGNE, F; SINGER, J; WALLEY, KR; MURTHY, S; PATRICK, D; REWA, OG; WINSTON, BW; MARSHALL, J; BOYD, J; TRAN, K; KALIL, A; MCCULOH, R; FOWLER, R; LUTHER, JM; RUSSELL, JA
title: ANGIOTENSIN RECEPTOR BLOCKERS AND ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 –META-ANALYSIS/META-REGRESSION ADJUSTED FOR CONFOUNDING FACTORS
date: 2021-04-06
journal: CJC Open
DOI: 10.1016/j.cjco.2021.03.001
sha: 989c6f20a2b32e9fb429d8d808033a601bafd891
doc_id: 723572
cord_uid: 0n4jq1m3

BACKGROUND Angiotensin receptor blockers (ARBs) and/or angiotensin converting enzyme (ACE) inhibitors could alter mortality of COVID-19, but existing meta-analyses which combined crude and adjusted results may be confounded by comorbidities being more common in ARBs/ACE inhibitors users. METHODS We searched PubMed/MEDLINE/Embase for cohort studies and meta-analysis reporting mortality by pre-existing ARB/ACE inhibitor treatment in hospitalized COVID-19 patients. Random effects meta-regression was used to compute pooled odds ratios for mortality adjusted for imbalance in age, sex and prevalence of cardiovascular disease, hypertension, diabetes mellitus and chronic kidney disease between users and non-users of ARBs/ACE inhibitors at the study-level during data synthesis. RESULTS In 30 included studies of 17,281 patients, 22%, 68%, 25%, and 11% had cardiovascular disease, hypertension, diabetes mellitus and chronic kidney disease. ARBs/ACE inhibitors use was associated with significantly lower mortality after controlling for potential confounding factors (OR 0.77 (95% CI: 0.62, 0.96)). In contrast, meta-analysis of ARBs/ACE inhibitors use was not significantly associated with mortality when all studies were combined with no confounder adjustment performed (0.87 (95% CI: 0.71, 1.08)). CONCLUSIONS ARBs/ACE inhibitors use was associated with decreased mortality in cohorts of COVID-19 patients after adjusting for age, sex, cardiovascular disease, hypertension, diabetes and chronic kidney disease. Unadjusted meta-analyses may not be appropriate for determining whether ARBs/ACE inhibitors are associated with mortality of COVID-19 because of indication bias.

The Coronavirus Disease-2019 (COVID-19) is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which has resulted in unprecedented global morbidity and mortality. The World Health Organization (WHO) and other groups are performing numerous randomized controlled trials (RCTs) of vaccines and novel therapeutic agents to target SARS-CoV-2. However, the critical illness and many complications of COVID-19 are caused in part by SARS-CoV-2's binding and inhibiting ACE2 (1, 2) and the consequent dysregulated host response.

SARS-CoV-2, H1N1, and H5N1(3) down-regulate ACE2. SARS-CoV-2 is then endocytosed, and surface ACE2 is down-regulated(1), thereby increasing angiotensin II (ATII a potent vasoconstrictor) in COVID- 19 because ACE2 catalyzes conversion of angiotensin II to angiotensin 1-7 (4) . Down-regulation of ACE2 occurs in H1N1, H5N1, H7N9, and SARS (5) (6) (7) (8) infection, leading to worsened lung injury in influenza models (5) (6) (7) , and increased viral load, disease progression and mortality (9) . Accordingly, angiotensin receptor blockers (ARBs) and angiotensin converting enzyme (ACE) inhibitors are candidate therapies for COVID-19 because they block excessive angiotensin II.

There is clinical uncertainty regarding the safety and effectiveness of ARBs/ACE inhibitors in COVID-19

because of conflicting cohort studies and even conflicting meta-analyses. There is an inherent potential bias in cohort studies of use of ARBs or ACE inhibitors in COVID-19 because patients who are on ARBs or ACE inhibitors have underlying comorbidities, including chronic cardiovascular disease, hypertension, diabetes mellitus and chronic kidney disease, that increase risk of complications and/or death in COVID- 19 . Accordingly, one must adjust for indication bias in patients who are on or not on ARBs or ACE inhibitors.

Some prior meta-analyses and studies found that use of ARBs and/or ACE inhibitors were not associated with altered mortality (10) (11) (12) (13) (14) (15) (16) , while one meta-analysis found that ACE inhibitors but not ARBs were associated with decreased COVID-19 mortality or critical illness (17) and others found that the use of ARBs or ACE inhibitors was associated with decreased mortality overall (18, 19) or in patients with cardiovascular disease (20) or hypertension (21) (22) (23) (24) (25) . The reason for these conflicting results could partly be due to methodological differences. Several meta-analyses (10, 11, 18, 19, 25) restricted their main or sensitivity analysis to studies that reported adjusted results and thus limited the number of studies that could be included. In contrast, other meta-analyses (12) (13) (14) (15) (16) (17) (21) (22) (23) (24) have combined only crude results together or improperly combined unadjusted and adjusted results together thus may suffer from indication bias, and/or combined incompatible adjusted effect measures together (odds ratio and hazard ratio) to obtain the pooled estimates which might yield biased results.

Meta-regression traditionally is used to examine the relationship between effect estimates of the included studies (e.g., odds ratio) and study-level covariates (e.g., proportion of patients with hypertension in each study). Several prior meta-regression analyses (17, 23, 26, 27) have examined the effects of average age, sex distribution or overall comorbidity prevalence of the included studies on patient outcome for ARBs/ACE inhibitors users vs. non-users. A less well-known use of meta-regression is that it can be utilized to obtain pooled effect estimates adjusted for study-level covariates(28). In the current context, meta-regression provides a methodologically attractive approach to explicitly adjust the crude results for confounding, including indication bias, during data synthesis and further combine them with existing adjusted results to form a pooled adjusted estimate. To the best of our knowledge, no meta-analysis of association of uses of ARBs and/or ACE inhibitors with mortality of COVID-19 has explicitly adjusted the crude results for imbalance in comorbidities between ARBs/ACE inhibitors users and non-users and properly combined them with existing adjusted results through meta-regression.

We hypothesized that ARBs and/or ACE inhibitors are associated with decreased mortality in analyses adjusted for underlying comorbidities.

Review and Meta-Analyses (PRISMA) statements (29) (Supplementary Table S1 ).

We conducted a literature search of PubMed/MEDLINE on August 19, 2020 for cohort and case-control studies that reported the frequencies of ARB or ACE inhibitors treatment and mortality in hospitalized patients infected with COVID-19 (Supplementary Appendix S1). More specifically, the studies evaluated the associations between prior use (i.e. pre-hospitalization chronic use) of ARBs and/or ACE inhibitors in hospitalized patients infected with COVID-19. A further search of PubMed and Embase was performed on November 17, 2020 to identify meta-analysis for the use of ARBs/ACE inhibitors and mortality in COVID-19 (Supplementary Appendix S1 & S2). Two authors (AC and TL) screened titles and abstracts to identify relevant studies.

Studies were included if they provided data for at least 10 hospitalized COVID-19 patients. For the purpose of performing meta-regression, studies also need to report either i) frequency of ARBs/ACE inhibitors use by patients, number of deaths by ARBs/ACE inhibitors usage and the following patient characteristics by ARBs/ACE inhibitors usage: age, sex and prevalence of the comorbidities of interest (chronic cardiovascular disease, hypertension, diabetes mellitus and chronic kidney disease) or ii) adjusted odds ratio of mortality for ARBs/ACE inhibitors usage. We included full-text peer-reviewed articles, peer reviewed articles published ahead of print as well as letters and commentaries. Other studies meeting the inclusion criteria were identified from the references in review articles and other metaanalyses. Only articles in English were included in the final analysis. We excluded non-peer-reviewed articles, article abstracts, incomplete articles, research posters, conference abstracts, books, theses and retracted articles.

Information on age, sex, comorbidities, ARBs/ACE inhibitors usage, mortality and adjusted odds ratio of mortality for ARBs/ACE inhibitors usage were extracted independently by two authors (AC and TL).

The Newcastle-Ottawa Scale (30) was used to assess the quality of the included studies. Studies with NOS scores of ≥7 were regarded as high quality, 4-6 as fair quality and <4 as low quality.

Pooled odds ratio (OR) of mortality for ARBs/ACE inhibitors use was computed within each study type (studies reported only crude results vs. studies with results adjusted for confounders) using random effects (RE) meta-analysis based on the DerSimonian-Laird model. Publication bias was examined through visual inspection of the funnel plot for asymmetry. Statistical heterogeneity was assessed by τ 2 , I 2 and Cochran's Q test.

Random effects meta-regression was further used to compute the pooled odds ratio by combining the results from all studies (both crude and confounder adjusted studies). For studies with only crude results reported, meta-regression adjusted for the difference in average age, sex distribution and the prevalence of the following comorbidities, as defined by the individual studies (cardiovascular disease, hypertension, diabetes mellitus and chronic kidney disease) between users and non-users of ARBs/ACE inhibitors. The choice of these four comorbidities is because they are the commonest reasons for prescribing ARBs and/or ACE inhibitors, and they are the commonest comorbidities associated with COVID-19 and death due to COVID-19. For confounder adjusted studies, meta-regression did not apply any further adjustment to the reported odds ratio.

Meta-regression examined the relationship between the degree of imbalance in mean age, gender distribution and comorbidity prevalence of ARBs/ACE inhibitors users vs. non-users and the odds ratio for mortality of ARBs/ACE inhibitors users vs. non-users. It also provided the pooled effect size adjusted for age, sex and comorbidity. The outcome variable was the log of the odds ratio (OR) for mortality. Studies that reported only crude results used the unadjusted odds ratio as the outcome variable, while confounder adjusted studies used the adjusted odds ratio. The regression model included the mean age ratio, ratio of the percentage of male and comorbidity prevalence ratio between the two groups as adjustment variables. For studies which reported adjusted results, one would interpret the reported results as if the two groups were adjusted to be balanced in terms of the confounders. Even though some of the included studies did not adjust for all the variables we considered herein, we believe that the authors of these studies would have examined the potential confounders and adjusted for those that were imbalanced between groups to obtain the adjusted results. Thus, for the adjustment variables we considered herein, we assumed that they have a value of 1 for these studies. This is essentially the same implicit assumption made when one combines adjusted ORs together to form a pooled estimate in a traditional meta-analysis.

Given the number of studies available, we were only able to adjust for a limited number of confounders simultaneously before there is a risk of overfitting the data (31, 32) . The general recommendation is that 10 to 20 studies are required for each adjustment variable(31) and the inclusion of six adjustment variables in our current analysis is over this recommendation. Thus, as a sensitivity analysis, we conducted an additional analysis which we adjusted only for age and sex and then four other separate analyses in which we adjusted for age, sex and each of the four comorbidities. We further conducted a sensitivity analysis to examine the robustness of the meta-regression approach. For confounder adjusted studies which provided patient characteristics (age, sex and comorbidities) by ARBs/ACE inhibitors usage, we used their crude data (mortality and patient characteristics) instead of the reported adjusted odd ratio for the metaregression analysis.

The adjusted pooled OR represented the OR for mortality if the two groups were to have the same mean age, sex distribution and comorbidity prevalence and was obtained from the estimated meta-regression model by setting the mean age ratio, male ratio and comorbidity prevalence ratio to one.

Random effects meta-analysis and meta-regression were performed using the meta package in R 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria). P <0.05 was considered statistically significant.

After screening titles and abstracts, 76 full text articles and 28 meta-analyses (with literature search covered up to October 12, 2020) were reviewed (Figure 1) . We included 30 studies with a total 17,281 patients hospitalized with COVID-19. Thirteen studies reported only crude results for mortality, while 17 reported adjusted odds ratio for mortality. Among the 13 crude studies, 1 reported adjusted hazard ratio of mortality, 1 reported odds ratio of mortality within pre-existing ARBs/ACE inhibitors users for continuation vs. discontinuation of treatment during hospitalization and 3 reported adjusted odds ratios of the composite outcome of death or severe disease (Supplementary Table S2 ).

The baseline characteristics of patients in the included studies are shown in Table 1 . Among hospitalized COVID-19 patients, 22% (n=3161/14,682), 68% (n=9919/14,682), 25% (n=3621/14,370) and 11% (n=1079/9952) had cardiovascular disease, hypertension, diabetes mellitus and chronic kidney disease respectively. Mortality of patients taking either ARBs/ACE inhibitors was 19% (n = 847/4477) whereas this endpoint was reached in 15% (n= 1609/10,990) among those not taking ARBs/ACE inhibitors ( Table   2) . In three studies, information on continuing ARBs or ACE inhibitors was collected. Two showed that continuing ARBs or ACE inhibitors was significantly associated with decreased mortality (33, 34) while one reported an OR substantially less than one, but did not reach statistical significance (35) .

Among studies which reported only crude results (i.e., not adjusting for differences between groups in important prognostic factors) for mortality, the use of ARBs/ACE inhibitors was not significantly associated with mortality (OR 1.05 (95% CI: 0.69, 1.61; p=0.82)). The pooled OR among confounder adjusted studies was also not significant (0.80 (95% CI: 0.63, 1.00; p=0.055)). When combining all studies together without adjustment of confounders for the crude results studies, the pooled OR was not significant (0.87 (95% CI: 0.71, 1.08; p=0.21)) (Figure 2) Figure S1) .

After adjusting for age, sex, cardiovascular disease, hypertension, diabetes and chronic kidney disease, the use of ARBs/ACE inhibitors was associated with a significantly lower mortality when all studies were combined (OR: 0.77 (95% CI: 0.62, 0.96; p=0.022); Figure 2 ). This conclusion was unchanged in the sensitivity analyses which only adjusted for a subset of confounders to avoid the possibility of overfitting the data. The adjusted OR of mortality from one study (34) was reported separately for continuation of ARBs/ACE inhibitors vs. no therapy and for discontinuation of ARBs/ACE inhibitors vs. no therapy.

The former was much lower compared to other included studies and exclusion of this study from the analysis did not alter our conclusion (Figure 2) .

Nine confounder adjusted studies also provided the distribution for age, sex and comorbidities by ARBs/ACE inhibitors usage ( Table 2 ). Our conclusion was unchanged in the sensitivity analyses which replaced the reported adjusted odds ratio with crude data from these studies (Figure 2 ; pooled OR was not adjusted for chronic kidney disease as it was not reported in two of these studies).

All studies with adjusted results were deemed as good quality based on the Newcastle-Ottawa Scale (Supplementary Table S3 ). The quality of studies with only crude results was lower as the crude mortality data reported could be influenced by indication bias. Accordingly, we attempted to minimize this impact analytically through meta-regression. The exception was the Hu study (36) for which the poor quality was mainly due to insufficient description of how the data was extracted. Exclusion of this study did not alter our conclusion (Figure 2) .

The use of ARBs and the use of ACE inhibitors were associated with significantly decreased mortality in observational studies of hospitalized patients with COVID-19 after adjusting for age, sex, cardiovascular disease, hypertension, diabetes and chronic kidney disease. In contrast, we found that the use of ARBs and the use of ACE inhibitors were not associated with significantly decreased mortality in unadjusted analyses possibly because patients on ARBs and patients on ACE inhibitors had more comorbidities and this imbalance may have contaminated the crude association between ARBs/ACE inhibitors use and mortality.

However, for both the analysis restricted to confounder adjusted studies and the unadjusted analysis by meta-regression, the point estimate of the pooled OR and most of the 95% confidence interval were less than 1, suggesting that it has the possibility of being an important effect. There was substantial overlap in the confidence intervals for the pooled OR from the adjusted and unadjusted meta-regression partly because the same set of data from the adjusted studies was used in both analyses. The degree of indication bias in the unadjusted meta-regression analysis clearly would depend on the number of included studies which only have crude results and the severity of indication bias in these studies. In particular, for studies which have restricted the analysis population to patients with a specific comorbidity (e.g., hypertension), the degree of such bias might be lower as the reported crude results have implicitly accounted for that particular comorbidity.

To our knowledge, no meta-analysis of ARBs and ACE inhibitors in COVID-19 has properly combined unadjusted and adjusted results by explicitly account for confounders during data synthesis and so our findings must be interpreted as hypothesis generating. Among the included studies, 17 reported adjusted odds ratio of mortality and by applying the meta-regression approach, it allowed us to increase the total number of studies to be included by also using data from studies that reported only crude results to form an overall adjusted odds ratio. This increased the statistical power of our analysis.

We emphasize that observational studies of use of ARBs and ACE inhibitors in COVID-19 are commonly confounded by indication bias. Prior research have suggested that there was a high prevalence of comorbidities, including chronic cardiovascular disease, hypertension, diabetes mellitus and chronic kidney disease occurring in 30-50% of COVID-19 patients(37-39) and these co-morbidities themselves increase the risk of complications and/or death in COVID-19 (40) (41) (42) (43) (44) . Patients with these comorbidities are often treated with ARBs or ACE inhibitors.

Canadian hypertension guidelines recommend ARBs if ACE inhibitors are not tolerated (45) , and ARBs and ACE inhibitors are very commonly prescribed (59% of hypertension (46) , 35% of hypertensive patients with chronic kidney disease (47) and 32% of diabetics (48) ). ARBs/ ACE inhibitors are recommended first line therapy in Canadian heart failure guidelines (49) . They were used in 50-70% of heart failure patients in Alberta, Canada (50) and 52-87% of heart failure patients in other countries (51) (52) (53) .

For all these reasons, one must adjust for indication bias in patients who are on or not on ARBs or ACE inhibitors when assessing the effect of these drugs on outcomes of COVID-19.

However, our findings are limited because a cohort association study is generally limited in addressing causation. There may be variables that we did not adjust for which confound the analyses and the results, and so it is not possible to address causal relationship. For example, ARBs and ACE inhibitors may only be tolerated in patients who have less severe disease (i.e. the underlying comorbidities) and who thus have lower mortality of COVID-19 such that the underlying severity of disease and not the use of ARBs or ACE inhibitors caused the lower mortality.

However, we suggest that only randomized controlled trials of ARBs and ACE inhibitors in COVID-19

can directly address causation, that ARBs and/or ACE inhibitors alter mortality of COVID-19. There are several such RCTs ongoing and one conference presentation (54) of a randomized controlled trial (n = 659) from Brazil of stopping or continuing ARBs and ACE inhibitors reports that ARBs and/or ACE inhibitors did not alter mortality of COVID-19 (2.7% vs. 2.8% respectively).

Among the three included studies in our manuscript which reported comparison of continuation versus discontinuation of ARBs or ACE inhibitors, they found that mortality was lower for those who continued ARBs or ACE inhibitors. However, we suggest that cohort studies that address the therapeutic benefits of continuation of ARBs or ACE inhibitors are confounded by the fact that the decision to discontinue could partly be driven by disease progression or side effects of the treatment. Although the current recommendation by scientific societies is not to discontinue treatment, we agree that further studies are needed such as trials that are registered that randomize patients already on ARBs or ACE inhibitors to continue or discontinue the ARBs or ACE inhibitors.

As for H1N1 and H5N1, ACE 2 is the receptor for COVID-19(2) and SARS-CoV-2 downregulates ACE2(1). Downregulation of ACE2 by SARS-Cov-2 dysregulates the renin angiotensin system, leading to increased plasma levels of angiotensin II in COVID-19. Plasma angiotensin II levels are increased in COVID-19 patients compared to healthy control(4) and higher in critically ill than non-critically ill COVID-19 patients (55) . Losartan (an ARB) decreases viral replication and lung injury in murine influenza pneumonia (56) . Consequently, ARBs and ACE inhibitors are suitable drugs to evaluate in COVID-19 because they inhibit excess angiotensin II through two different mechanisms by blocking the angiotensin II type 1 receptor or by inhibiting production of angiotensin II respectively, and thus may have different effects on outcomes of COVID-19.

We did not examine the effects of ARBs and ACE inhibitors separately in our current analysis since most included studies evaluated the two effects together. Based on a different set of three studies, one previous meta-analysis (16) did not find the effect of ARBs on mortality to be different from that of ACE inhibitors, while another (27) found that ARBs but not ACE inhibitors reduced mortality compared to non-users. A recent meta-analysis which included both hospital admitted and non-admitted patients (24) has synthesized these two effects separately using crude mortality data from 9 studies restricted to hypertensive patients and found no significant association between ARBs or ACE inhibitors and mortality.

There are other limitations of our study. First, as we do not have patient level data, we could only adjust for potential confounders at the study level. Second, to avoid overfitting the data, we only included major confounding variables in the analysis. Also, for studies reported adjusted results, not all of them have adjusted for the confounder variables we considered herein, (i.e., age, sex and comorbidities). It is possible that the selection of adjustment variables was pre-specified based on prior knowledge rather than chosen based on observed imbalance. Thus, there is a possibility that there is residual confounding which explains the association. It is also possible that our findings are subject to publication bias, although this should be limited given the urgency of COVID-19 research. Another limitation is that we have restricted our literature search to English articles and thus could suffer from language bias. Finally, some of the included studies have censored the patients who were still hospitalized at the time of data extraction and reported them as survivors, which might not accurately reflect the final outcome of these patients.

In conclusion, meta-regression analyses found that the use of ARBs/ACE inhibitors were associated with significantly decreased mortality of COVID-19 after adjusting for age, sex, cardiovascular disease, hypertension, diabetes and chronic kidney disease. Unadjusted meta-analyses may not be appropriate for determining whether ARBs or ACE inhibitors are associated with mortality of COVID-19 because of the potential for indication bias. In contrast, combining unadjusted and adjusted results with careful consideration of indication bias through meta-regression is methodologically sound and increases the statistical power of the analysis. While association cannot prove causality, our findings support the need for randomized controlled trials evaluating ARBs and ACE inhibitors as therapeutic interventions to reduce mortality in hospitalized patients with COVID-19.

We thank the patients and families who participated in the ARBs CORONA I study which has increased our understanding of COVID-19. We also thank the many dedicated clinicians (doctors, nurses, therapists and others) who cared for these patients and comforted their families. We also thank the investigators in the ARBs CORONA program for their ongoing support and tireless collaboration (Supplementary Appendix S3). Cardiovascular disease includes coronary artery disease, congestive heart failure or heart failure, cardiopathy, ischemic heart disease, coronary heart disease, cardiovascular disease.

Information not reported by the study was denoted by a dash.

ACEi = ACE inhibitors * Median age was shown if mean age was not reported. † Numbers were for ACEi vs. no therapy in the first row and for ARBs vs. no therapy in the second row. ‡ Numbers were for ARBs/ACEi continued vs. no therapy in the first row and for ARBs/ACEi discontinued vs .no therapy in the second row. § Numbers were for ACEi vs. no ACEi

Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients

The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis

ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis

A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers

Mortality in COVID-19 patients treated with ACEIs/ARBs: Re-estimated meta-analysis results following the Mehra et al. retraction

Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis

Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities

Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis

Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis

Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Metaanalysis. American journal of cardiovascular drugs : drugs, devices, and other interventions

The characteristics and outcomes of 681 severe cases with COVID-19 in China

Decreased Mortality of COVID-19 with Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis. Hypertension. 2020. 22

The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis

Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and metaanalysis

Renin-angiotensinaldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis

Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses

Regression Modeling Strategies

Doing Meta-Analysis in R: A Hands-on Guide

Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome

Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality

Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection

COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no infulence on the clinical severity and outcome

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States

Age and Multimorbidity Predict Death Among COVID-19 Patients

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children

Anti-Hypertensive Medication Combinations in the United States

Trends in Angiotensin-Converting Enzyme Inhibitor and

Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States

Utilization of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients diagnosed with diabetes: Analysis from the National Ambulatory Medical Care Survey

Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure

Kidney Function, ACE-Inhibitor/Angiotensin Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study

Evaluation of drugs used in chronic heart failure at tertiary care centre: a hospital based study

Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure

Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study

Hot Line: Can ACEis and ARBs be safely continued in patients hospitalised with COVID-19? Results from the BRACE CORONA trial 2020

Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients

Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust

Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens

The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Long-Term ACE Inhibitor/ARB Use Is Associated with Severe Renal Dysfunction and Acute Kidney Injury in Patients with severe COVID-19: Results from a Referral Center Cohort in the North East of France

Could Anti-Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID-19 Infection? Data From Centers of Southern Italy

Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19

Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19

Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study. Hypertension

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19

RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies

Angiotensin-Converting Enzyme Inhibitors Or Angiotensin Ii Receptor Blockers And Prognosis Of Hypertensive Patients Hospitalized With Covid-19

Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives

Inhibitors of the reninangiotensin-aldosterone system and COVID-19 in critically ill elderly patients

Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study

Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population

Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study

Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension

Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?

Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients

Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis

In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension

 Table 1 . Characteristics of studies included in meta-analysis. Cardiovascular disease includes coronary artery disease, congestive heart failure or heart failure, cardiopathy, ischemic heart disease, coronary heart disease, cardiovascular disease.

Information not reported by the study was denoted by a dash.